CN104981250A - 用于治疗贫血的方法 - Google Patents

用于治疗贫血的方法 Download PDF

Info

Publication number
CN104981250A
CN104981250A CN201380067832.9A CN201380067832A CN104981250A CN 104981250 A CN104981250 A CN 104981250A CN 201380067832 A CN201380067832 A CN 201380067832A CN 104981250 A CN104981250 A CN 104981250A
Authority
CN
China
Prior art keywords
gdf11
actriia
antagonist
seq
actriib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380067832.9A
Other languages
English (en)
Chinese (zh)
Inventor
维多利亚·松
拉杰什·乔普拉
奥利维尔·赫尔米内
伊凡·克鲁兹莫拉
迈克尔·杜赛特
蒂亚戈·特罗瓦蒂马切尔
奥雷利·弗里克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Priority to CN202011542063.1A priority Critical patent/CN112957462A/zh
Priority to CN202011541918.9A priority patent/CN112933223A/zh
Publication of CN104981250A publication Critical patent/CN104981250A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201380067832.9A 2012-10-24 2013-10-23 用于治疗贫血的方法 Pending CN104981250A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202011542063.1A CN112957462A (zh) 2012-10-24 2013-10-23 用于治疗贫血的方法
CN202011541918.9A CN112933223A (zh) 2012-10-24 2013-10-23 用于治疗贫血的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261718128P 2012-10-24 2012-10-24
US61/718,128 2012-10-24
PCT/US2013/066353 WO2014066487A2 (en) 2012-10-24 2013-10-23 Methods for treating anemia

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202011541918.9A Division CN112933223A (zh) 2012-10-24 2013-10-23 用于治疗贫血的方法
CN202011542063.1A Division CN112957462A (zh) 2012-10-24 2013-10-23 用于治疗贫血的方法

Publications (1)

Publication Number Publication Date
CN104981250A true CN104981250A (zh) 2015-10-14

Family

ID=50545463

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201380067832.9A Pending CN104981250A (zh) 2012-10-24 2013-10-23 用于治疗贫血的方法
CN202011541918.9A Pending CN112933223A (zh) 2012-10-24 2013-10-23 用于治疗贫血的方法
CN202011542063.1A Pending CN112957462A (zh) 2012-10-24 2013-10-23 用于治疗贫血的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202011541918.9A Pending CN112933223A (zh) 2012-10-24 2013-10-23 用于治疗贫血的方法
CN202011542063.1A Pending CN112957462A (zh) 2012-10-24 2013-10-23 用于治疗贫血的方法

Country Status (9)

Country Link
US (1) US20150266950A1 (cg-RX-API-DMAC7.html)
EP (2) EP3527219A1 (cg-RX-API-DMAC7.html)
JP (3) JP6401172B2 (cg-RX-API-DMAC7.html)
CN (3) CN104981250A (cg-RX-API-DMAC7.html)
AU (4) AU2013334660B2 (cg-RX-API-DMAC7.html)
CA (1) CA2889286A1 (cg-RX-API-DMAC7.html)
HK (1) HK1214504A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ747350A (cg-RX-API-DMAC7.html)
WO (1) WO2014066487A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107011430A (zh) * 2017-04-07 2017-08-04 哈尔滨医科大学 一种具有生物学活性的截短的生长分化因子11及其制备方法
CN112601538A (zh) * 2018-05-09 2021-04-02 科乐斯疗法公司 激活素受体iia型变体及其使用方法

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
BRPI0618947B1 (pt) 2005-11-23 2022-07-19 Acceleron Pharma Inc Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
TWI584815B (zh) 2007-02-01 2017-06-01 艾瑟勒朗法瑪公司 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
MX2009008510A (es) 2007-02-09 2010-01-15 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer.
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
DK3750552T5 (da) 2008-08-14 2024-08-26 Acceleron Pharma Inc Gdf-fælder
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
MX355042B (es) 2009-06-08 2018-04-02 Acceleon Pharma Inc Metodos para aumentar adipositos termogenicos.
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
CA2817008A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma Inc. Actriia binding agents and uses thereof
JP6401172B2 (ja) * 2012-10-24 2018-10-10 セルジーン コーポレイション 貧血の治療方法
RU2678117C2 (ru) 2012-11-02 2019-01-23 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
JP2017509647A (ja) * 2014-03-21 2017-04-06 アクセルロン ファーマ， インコーポレイテッド アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
EP3227675B1 (en) 2014-12-03 2023-03-15 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
WO2016128523A1 (en) * 2015-02-12 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
TWI814187B (zh) * 2015-05-13 2023-09-01 美商西建公司 使用ACTRII配位體捕捉以治療β-地中海型貧血
EP3298034A4 (en) 2015-05-20 2019-02-13 Celgene Corporation IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS
EP3370754B1 (en) 2015-11-04 2026-04-29 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
AU2017296040C1 (en) 2016-07-15 2023-06-22 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
LT3490582T (lt) 2016-07-27 2024-07-25 Acceleron Pharma Inc. Kompozicijos, skirtos naudoti gydant mielofibrozę
CA3043184A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
EP3706777B1 (en) 2017-11-09 2024-05-22 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
WO2020257587A1 (en) * 2019-06-19 2020-12-24 Cornell University Methods of promoting erythropoiesis and overcoming erythropoitein resistance in patients
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
EP4121078A4 (en) 2020-03-20 2024-08-14 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF
US20230174620A1 (en) 2020-04-28 2023-06-08 Acceleron Pharma Inc. Actrii proteins and use in treating post-capillary pulmonary hypertension
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
CN113801880B (zh) * 2021-07-27 2024-11-01 浙江大学 一种通过靶向敲除基因建立的早衰细胞模型及其sgRNA、构建方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150577A1 (en) * 1994-07-08 2002-10-17 Johns Hopkins University School Of Medicine Use of antibodies specific for growth differentiation factor-11
CN102131515A (zh) * 2008-06-26 2011-07-20 阿塞勒隆制药公司 激活素-actrii的拮抗剂及在提高红细胞水平中的用途
WO2012064771A1 (en) * 2010-11-08 2012-05-18 Acceleron Pharma, Inc. Actriia binding agents and uses thereof
CN102655872A (zh) * 2009-08-13 2012-09-05 阿塞勒隆制药公司 Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US7795202B2 (en) 1997-08-04 2010-09-14 Neurorepair, Inc. Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a)
NZ509609A (en) * 1998-07-28 2003-11-28 Univ Johns Hopkins Med Disrupting growth differentiation factor-11 (GDF-11) to increase the muscle and bone tissue in animals
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
PL374966A1 (en) 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
JP2008534607A (ja) * 2005-03-30 2008-08-28 ワイス Ｂｍｐを投与することによって毛髪の成長を刺激するための方法
AU2006264339A1 (en) * 2005-07-01 2007-01-11 Acceleron Pharma Inc. Lefty, Lefty derivatives and uses therof
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
CA2672758C (en) 2006-12-18 2019-07-30 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
US8236751B2 (en) 2007-03-07 2012-08-07 The Johns Hopkins University Methods of increasing muscle mass using follistatin-like related gene (FLRG)
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
DK3750552T5 (da) 2008-08-14 2024-08-26 Acceleron Pharma Inc Gdf-fælder
US8216997B2 (en) * 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
WO2012027065A2 (en) * 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
JP6401172B2 (ja) * 2012-10-24 2018-10-10 セルジーン コーポレイション 貧血の治療方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150577A1 (en) * 1994-07-08 2002-10-17 Johns Hopkins University School Of Medicine Use of antibodies specific for growth differentiation factor-11
CN102131515A (zh) * 2008-06-26 2011-07-20 阿塞勒隆制药公司 激活素-actrii的拮抗剂及在提高红细胞水平中的用途
CN102655872A (zh) * 2009-08-13 2012-09-05 阿塞勒隆制药公司 Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
WO2012064771A1 (en) * 2010-11-08 2012-05-18 Acceleron Pharma, Inc. Actriia binding agents and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI Z ET AL.: "Transgenic overexpression of bone morphogenetic protein 11 propeptide in skeleton enhances bone formation", 《J BIO CHEM》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107011430A (zh) * 2017-04-07 2017-08-04 哈尔滨医科大学 一种具有生物学活性的截短的生长分化因子11及其制备方法
CN107011430B (zh) * 2017-04-07 2020-09-01 哈尔滨医科大学 一种具有生物学活性的截短的生长分化因子11及其制备方法
CN112601538A (zh) * 2018-05-09 2021-04-02 科乐斯疗法公司 激活素受体iia型变体及其使用方法
CN112601538B (zh) * 2018-05-09 2025-08-19 科乐斯疗法公司 激活素受体iia型变体及其使用方法

Also Published As

Publication number Publication date
AU2020203198B2 (en) 2021-12-23
AU2018256635A1 (en) 2018-11-22
JP2018184430A (ja) 2018-11-22
AU2022201923A1 (en) 2022-04-14
US20150266950A1 (en) 2015-09-24
EP2911682A2 (en) 2015-09-02
WO2014066487A2 (en) 2014-05-01
NZ747350A (en) 2020-07-31
CN112933223A (zh) 2021-06-11
JP2020183390A (ja) 2020-11-12
AU2013334660B2 (en) 2018-08-09
EP3527219A1 (en) 2019-08-21
EP2911682A4 (en) 2016-03-23
HK1214504A1 (zh) 2016-07-29
JP6401172B2 (ja) 2018-10-10
JP2016503398A (ja) 2016-02-04
AU2020203198A1 (en) 2020-06-11
WO2014066487A3 (en) 2014-06-19
CN112957462A (zh) 2021-06-15
AU2013334660A1 (en) 2015-05-14
CA2889286A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
JP7146850B2 (ja) 貧血の治療に使用するためのバイオマーカー
JP6401172B2 (ja) 貧血の治療方法
CN102131515B (zh) 激活素‑actrii的拮抗剂及在提高红细胞水平中的用途
JP5778576B2 (ja) アクチビン−ＡｃｔＲＩＩａアンタゴニストを投薬する方法および処置される患者をモニターする方法
HK40012688A (en) Methods for treating anemia
HK40023193A (en) Biomarker for use in treating anemia
HK1213948B (en) Biomarker for use in treating anemia
NZ743635B2 (en) Biomarker for use in treating anemia
NZ743635A (en) Biomarker for use in treating anemia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20151014

RJ01 Rejection of invention patent application after publication